The Hong Kong Neurosurgical Society

28th ANNUAL SCIENTIFIC MEETING

UPDATES ON TRAUMATIC BRAIN INJURY AND NEUROCRITICAL CARE

Hybrid Meeting

26 - 27 November 2021

Cordis Hong Kong at Langham Place

www.ns.org.hk

FI 18 1.0 09/2019/A-CNHK

IMAGE1 S™ Rubina – mORe to discover

- Native 4K image chain
- Improved 3D image quality
- Automatic horizon control
- New OPAL1® NIR/ICG modes
- Laser-free LED light source

STORZ
KARL STORZ — ENDOSKOPE
THE DIAMOND STANDARD

75 Years

KARL STORZ SE & Co. KG, Dr.-Karl-Storz-Straße 34, 78532 Tuttlingen/Germany
KARL STORZ Endoscopy (Shanghai), 3000 Longdong Avenue, 201203, Shanghai, People's Republic of China
www.karlstorz.com

CONTENTS

WELCOME MESSAGE

Dear Colleagues and Friends,

Welcome to our 28th Annual Scientific Meeting of the Hong Kong Neurosurgical Society. While local COVID situation improved and better days returned in Hong Kong, we should be with our friends again; we should meet again, physically whenever possible to facilitate exchange of ideas, skills and knowledge, and not content with those intangible virtual meetings.

Our theme this year is "Updates on Traumatic Brain Injury and Neurocritical Care". It is our great honour to have Prof. Peter Hutchinson, NIHR Research Professor at the Department of Clinical Neurosciences, University of Cambridge and Honorary Consultant Neurosurgeon at Addenbrooke's Hospital, Cambridge as our keynote speaker. He will share with us the latest management as well as the global perspective and research in traumatic brain injury.

Our next renowned keynote speaker is Prof. Mark Wilson, Professor of Practice of Brain Injury at Imperial College London and Honorary Professor (The Gibson Chair) of Pre-Hospital Care at the Royal College of Surgeons of Edinburgh. He will elucidate the pathophysiology in intracranial pressure and give us advices on sports-related brain injuries in UK perspective.

Prof. Iype Cherian, Director and Chair of Nobel Institute of Neuroscience at Nobel Medical College and Teaching Hospital in Biratnagar in Nepal will explain the anatomy and physiology of intracranial cisterns and the surgical techniques for cisternostomy in traumatic brain injury. Prof. Sui-sum Kung, Attending Neurosurgeon and Neurointensivist at the Department of Neurosurgery in Kaohsiung Medical University Hospital will enlighten us the neurocritical care aspects in the management of brain injuries.

Finally, I would like to take this opportunity to thank Dr. Calvin Mak and the organizing committee, the Secretariat, all helpers, the commercial sponsors, and all of you who participate. I hope all of you would find the programme interesting and useful to your practice and have a fruitful weekend.

Dr. Michael Lee

President
The Hong Kong Neurosurgical Society

WELCOME MESSAGE



Dear Members and Friends,

It is my honor to announce the commencement of our 28th Annual Scientific Meeting of the Hong Kong Neurosurgical Society. As the COVID-19 pandemic is under better control, we are glad to resume our usual ASM as a hybrid meeting - physically at Cordis and parallel virtual broadcast. Despite technology has greatly helped with knowledge transfer, we have all missed the mingling and chatting during and after the Annual Scientific Meeting.

Head injury, or a better term Traumatic Brain Injury, is an important neurosurgical condition that neurosugeons treat every day, ranging from trivial head injury to severe traumatic brain injury requiring neurocritical care. We are glad to have invited four world class experts to share with us under the meeting theme of "Updates on Traumatic Brain Injury and Neurocritical Care" , including Prof. Peter Hutchinson, Prof. Mark Wilson, Prof. Iype Cherian and Prof. Sui-sum Kung. Similar to last year, we also have two dedicated sessions from the Spine Chapter and Stereotactic Radiosurgery Chapter of the HKNS.

I would like to express my sincere thanks to Dr. Michael Lee for his leadership, all speakers, Organizing Committee, IT Subcommittee, the Secretariat, commercial sponsors, and all of you who are participating both online and in person. Enjoy the programme!

Hope to see you all in person in 2021, and stay healthy!

Dr. Calvin Mak
Honorary Secretary

ORGANIZING COMMITTEE

COUNCIL MEMBERS & ORGANISING COMMITTEE

President	:	Dr. Michael LEE
Vice President	:	Dr. Sui-to WONG
Honorary Secretary	:	Dr. Calvin MAK
Honorary Treasurer	:	Dr. Jason CHOW
Council Members	:	Dr. David CHAN
		Dr. Alberto CHU
		Dr. Lai-fung LI
		Dr. Kar-ming LEUNG
		Dr. Yin-chung PO

IT SUBCOMMITTEE

Dr. Jason HO & Dr. Ben NG (Team Leader)
Dr. Eric CHEUNG
Dr. Harry CHEUNG
Dr. Cheuk-him HO
Dr. Ronald LI
Dr. Ben LUK
Dr. Michael SEE
Dr. Jennie YEUNG

PHOTOGRAPHER

Ms Amelia YUNG

GUEST FACULTIES

The Organising Committee would like to thank the following guest faculties for their invaluable contributions to the 28th Annual Scientific Meeting

Prof. Peter HUTCHINSON

Professor of Neurosurgery, University of Cambridge
Honorary Consultant Neurosurgeon, Cambridge University Hospitals NHS Foundation Trust
Director of Clinical Research, Royal College of Surgeons of England
NIHR Research Professor
Director of Clinical Studies Robinson College

Prof. Mark WILSON

Consultant Neurosurgeon (Imperial College NHS Trust)
Pre-Hospital Care Specialist (Kent Surrey Sussex Air Ambulance)
Professor of Practice Brain Injury, Imperial College London
Gibson Chair (Hon Prof) of Pre-Hospital Care, Royal College of Surgeons Edinburgh

Prof. Iype CHERIAN

Director, Neurosciences
Krishna institute of Medical Sciences
India

Prof. Sui-sum KUNG

Attending Neurosurgeon and Neurointensivist
Department of Neurosurgery
Kaohsiung Medical University Hospital

Not available in all markets. Vault-free based on typical system use and patient volume.

FIRST-IN-KIND. VAULT-FREE. COBALT-FREE.

World-class radiosurgery to treat more patients in more places.

Take an interactive tour of ZAP-X®:
zapsurgical.com/vr-tour

UPH Limited
E: tcy@up-healthcare.com | P: +852-92832429

ZAP®

THAT WAS THEN. **THIS IS NEXT.**

METICULOUS. FOCUSED. PRECISE.

Stealth Autoguide™ cranial robotic guidance platform accurately aligns to your surgical plans for cranial procedures.

REAL-TIME VISUALIZATION, FEEDBACK, AND ROBOTIC MOVEMENT

Visualase™

Stealth Autoguide™ aligns the bone anchor to a planned trajectory. A flexible Visualase™ laser catheter is passed through the bone anchor to the target area.

Depth Electrodes

Stealth Autoguide™ assists in the placement of sEEG bolts to enable the placement of depth electrodes. Allowing you to place multiple sEEG bolts.

Biopsy

Stealth Autoguide™ aligns to your surgical plan to place the biopsy needle with direct depth stop calculation and confirmation of biopsy location with biopsy needle navigation.



FOR MORE INFORMATION:
MEDTRONIC HONG KONG MEDICAL LIMITED
1104-11, 11/F, Tower 1, The Gateway, Tsim Sha Tsui, Kowloon
TEL: (852) 2919 1300 FAX: (852) 2838 0749
www.medtronic.com

Medtronic

GUEST FACULTIES

Dr. Peter HUTCHINSON

BSc MBBS FFSEM FRCS(SN) PhD FMedSci
Professor of Neurosurgery, University of Cambridge
Honorary Consultant Neurosurgeon, Cambridge University Hospitals NHS Foundation Trust
Director of Clinical Research, Royal College of Surgeons of England
NIHR Research Professor
Director of Clinical Studies Robinson College

Peter Hutchinson BSc (Hons), MBBS, PhD (Cantab), FRCS (Surg Neurol) FMedSci is Professor of Neurosurgery, NIHR Research Professor and Head of the Division of Academic Neurosurgery at the University of Cambridge. He is Director of Clinical Research at the Royal College of Surgeons of England. He holds an Honorary Consultant Neurosurgeon post at Addenbrooke's Hospital with a sub-specialist interest in the management of neuro-trauma, specifically head and traumatic brain injury.

He has a research interest in acute brain injury, utilising monitoring technology to increase the understanding of the pathophysiology of brain injury, and in the investigation and treatment of concussion. He also leads the international RESCUE studies evaluating the role of decompressive craniectomy in traumatic brain injury. He was awarded the Olivecrona Prize (the "Nobel Prize for Neurosurgery") for his work on cerebral metabolism in acute brain injury). He has co-authored over 500 publications (including NEJM, Lancet and Brain, and been lead applicant in over £15m of grants (including MRC and NIHR).

He is joint editor of the Oxford Textbook of Neurological Surgery and "Head Injury - A Multidisciplinary Approach".

He is Director of Clinical Studies at Robinson College, Past President of Clinical Neurosciences Section of the Royal Society of Medicine, Director of the Research Fund of the European Association of Neurosurgical Societies, Treasurer of the International Neurotrauma Society and Chief Medical Officer for the Formula One British Grand Prix.

GUEST FACULTIES

Prof. Mark WILSON

PhD MBBChir FRCS (SN) FIMC MRCA FRGS OBE
Consultant Neurosurgeon (Imperial College NHS Trust)
Pre-Hospital Care Specialist (Kent Surrey Sussex Air Ambulance)
Professor of Practice Brain Injury, Imperial College London
Gibson Chair (Hon Prof) of Pre-Hospital Care, Royal College of Surgeons Edinburgh

Mark Wilson is a Consultant Neurosurgeon (Imperial Hospitals NHS Trust) and Pre-Hospital Doctor (Kent, Surrey and Sussex Air Ambulance). He is also Clinical Professor of Brain Injury (Imperial College London) and Hon Professor (the Gibson Chair) of Pre-Hospital Care (Royal College of Surgeons Edinburgh). His specialist interests are traumatic and hypoxic brain injury. He has worked extensively overseas in many medical roles.

Mark is also co-founder and medical director of GoodSAM (www.goodsmapp.org), a platform that is revolutionising volunteering and emergency services around the world though crowd-sourcing care and the innovative use of video and artificial intelligence to aid emergency response. This, and work for www.clinic.co (providing a free advanced telemedicine service), has been recognised nationally and internationally.

GUEST FACULTIES

Prof. Iype CHERIAN

Director, Neurosciences
Krishna institute of Medical Sciences
India

Positions

Director, Neurosciences Krishna institute of Medical Sciences,
General Counselor, Asian CNS
Member WFNS anatomy committee
Member - UNESCO Neuroanatomy Executive board
Section Editor- Trauma for Surgical Neurology International
Described Cisternostomy
Described CSF shift edema
Described the cooling and cleaning of brain
Classification of extradural Carotid segments and relationships

GUEST FACULTIES

Prof. Sui-sum KUNG

Attending Neurosurgeon and Neurointensivist
Department of Neurosurgery
Kaohsiung Medical University Hospital

Positions

2010	Member of United State Neurocritical care society
2014 - 2017	Chinese congress of Neurosurgery - Neurocritical care board member
2016	Chinese Critical care association of Physician - Neurocritical care board member
2018	Vice-chairmen of traumatic brain injury committee, The International Chinese Federation of Neurosurgical Sciences
2019	Chairman, Neurocritical care committee, Taiwan Neurosurgical Society
	Member of education committee, Taiwan society of Critical Care Medicine
	Member of education committee, Taiwan society of Emergency and Critical care medicine
2020	Member of board of directors, Taiwan Neurotrauma and Critical care Society
	Member of critical care committee, Taiwan Surgical Association
Now	Attending Neurosurgeon and Neurointensivist, Kaohsiung Medical University Hospital
	Instructor of Taiwan Society of Critical Care Medicine
	Taiwan National Defense Medical College, Clinical associate professor

VENUE FLOOR PLAN

26th November 2021



Booth No.	Name of Sponsorship Company
1	MontsMed Company Limited
2	NewTech International Trading Limited
3	Prism Technologies Limited
4	B. Braun Medical (H.K.) Ltd.
5	Allergan Hong Kong Ltd
6	Mizuho Medical / Innoflx Limited
7	Stryker China Limited
8	Medtronic HK Medical Limited
9	Karl Storz Endosopy China Ltd
10	UPH Limited
11	Baxter Healthcare Ltd.
12	Zailab (Hong Kong) Limited
13	Zuellig Pharma Limited

VENUE FLOOR PLAN

27th November 2021



Booth No.	Name of Sponsorship Company
1	NewTech International Trading Limited
2	Prism Technologies Limited
3	MontsMed Company Limited
4	B. Braun Medical (H.K.) Ltd.
5	Allergan Hong Kong Ltd
6	Zuellig Pharma Limited
7	Mizuho Medical / Innoflx Limited
8	Stryker China Limited
9	Zailab (Hong Kong) Limited
10	UPH Limited
11	Karl Storz Endosopy China Ltd
12	Medtronic HK Medical Limited
13	Baxter Healthcare Ltd.

MIZUHO
INSTRUMENTS

MISET

ドラフト版

stryker

Simple. Versatile. **Brilliant.**

Sonopet iQ

Trusted resection and power

367%
faster fibrous tissue resection[1]

133%
faster bone cutting[1]

75%
more precise suction control[2]

48%
faster setup time[1]

Meet the new **Sonopet iQ**

Ultrasonic Aspirator System

Soft tissue resection / Fine bone dissection / All-in-one system

1. All comparative metrics and claims are Sonopet iQ compared to Sonopet 1. Stryker internal test data on file.
2. Sonopet iQ has improved suction control for delicate resection rates with 75% lower achievable pressure settings compared to the first generation Sonopet. Stryker internal data.

PROGRAMME AT-A-GLANCE

Programme at a glance

Venue: Ballroom I & II, 7/F, Cordis Hong Kong at Langham Place, Mongkok

Time		26 November 2021 (Friday)
8:00 - 8:30	POSTER PRESENTATION / EXHIBITION	Registration
8:30 - 8:40		**Welcome Speech** Dr Michael Lee
8:40 - 9:50		**Free Paper I - Trauma** Chairpersons: Dr. K.Y. Pang, Dr. Christopher Poon
9:50 - 10:00		Tea Break
10:00 - 10:30		**Interim Report on HKNS Research: Impact of Cranioplasty on Cerebral Perfusion and Cognitive Outcome** Dr. Calvin Mak, Dr David Chan, Dr. Anderson Tsang *on behalf of Research Subcommittee* Chairpersons: Dr. Derek Wong, Dr. H.T. Wong
10:30 - 11:30		**Free Paper II - Vascular** Chairpersons: Dr. Y.T. Kan, Dr. C.P. Tsang
11:30 - 12:30		**Keynote Lecture I - Prof. Iype Cherian** 1. Anatomy and physiology of intracranial cisterns 2. Surgical techniques for cisternostomy in Traumatic Brain Injury Chairpersons: Dr. H.M. Chiu, Dr. Dawson Fong
12:30 - 13:40		Lunch
13:40 - 14:10		**Extraordinary General Meeting of the Hong Kong Neurosurgical Society**
14:10 - 14:50		**Free Paper III - Spine** Chairpersons: Dr. Joseph Lam, Dr. Y.H. Tse
14:50 - 15:10		Tea Break
15:10 - 15:30		**Spine Chapter Lecture - Hong Kong Neurospine service and development** Dr. W.K. Mak, Dr. Calvin Mak, Dr. David Chan (Chapter Convenor) Moderators: Dr. C.F. Fung, Dr. Daniel Ng
15:30 - 16:30		**Keynote Lecture II - Prof. Mark Wilson** 1. Monro-Kellie 2.0: A new understanding of pathophysiology in intracranial pressure 2. Pre-hospital and early management in Traumatic Brain Injury 3. Sports and work related mild Traumatic Brain Injury - a UK perspective Chairpersons: Dr. F.C. Cheung, Dr. C.K. Wong

PROGRAMME AT-A-GLANCE

Venue: Ballroom I & II, 7/F, Cordis Hong Kong at Langham Place, Mongkok

Time		27 November 2021 (Saturday)	
08:00 - 08:30	POSTER PRESENTATION / EXHIBITION	Registration	
08:30 - 10:00		**Keynote Lecture III - Prof. Sui-sum Kung** 1. Implementation of guidelines in the management of severe Traumatic Brain Injury - Which one is better? 2. Thinking of the pathophysiological change - before writing your orders 3. Targeted temperature management (TTM) for neurocritical care - What you need to know? Chairpersons: Dr. Danny Chan, Dr. K.M. Leung	
10:00 - 10:20		Tea Break	
10:20 - 10:40		**Free Paper IV - Video** Chairpersons: Dr. Clarence Leung, Dr. T.C. Tan	
10:40 - 12:00		**Free Paper V - Tumor & Others** **Venue: ballroom I & II, 7/F** Chairpersons: Dr. S.T. Chan, Dr. W.K. Wong	10:40 am - 11:40 am **Venue: Ballroom III, 7/F** Nursing Session **Excellence in Neurocritical Patient Care Journey** Chairpersons: *Mr. M.K. Chu, Ms M.Y. Lok*
12:00 - 12:10		Group photo	
12:10 - 13:40		Lunch	
13:40 - 14:10		**Free Paper VI - Functional & Others** Chairpersons: Dr. K.H. Chan, Dr. Y.C. Po	
14:10 - 14:50		**Free Paper VII - Vascular** Chairpersons: Dr. K.M. Cheng, Dr. W.M. Lui	
14:50 - 15:10		Tea Break	
15:10 - 15:30		**SRS Chapter Lecture - Stereotactic Radiosurgery Practice in HA Hospitals** Dr K.Y. Yam (Chapter Convenor) Moderators: Dr. T.L. Poon, Dr. C.P. Yu	
15:30 - 16:55		**Keynote Lecture IV - Prof. Peter Hutchinson** 1. Current practice in management of moderate and severe Traumatic Brain Injury 2. Surgical treatment in severe Traumatic Brain Injury - evidence based practice 3. A global perspective and research in Traumatic Brain Injury Chairpersons: Dr. Y.W. Fan, Prof. W. Poon	
16:55 - 17:00		**Concluding Remarks** Dr Michael Lee	

TISSEEL
[Fibrin Sealant]

Introducing PRIMA

Next Generation Pre-filled Syringe



SPEED, PRECISION & CONTROL

- Broad Indication[1]
- Enhanced Clot Stability[2]
- Over 2,000 Publications[3]

Reference: 1. TISSEEL [Summary of Product Characteristics]. Vienna, Austria: Baxter International Inc. 2015. **2.** Seelich T.J. Tissucol: Biochemistry & Methods of Application. J. Head & Neck Pathol. 1982; 3:65-70. **3.** Baxter Data on File, Embase (1974 to 11/15/2019) and MEDLINE (1946 to week 2 in 11/2019) database searches.

Tisseel (In Synthetic Aprotinin) Solutions for Sealant (Frozen): (Please consult the Package insert before prescribing) **Composition: Component 1 (Protein solution for tissue adhesive):** Human fibrinogen (as clottable protein) 91 mg/ml Synthetic aprotinin 3000 KIU/ml **Component 2 (Thrombin solution):** Human thrombin 500 IU/ml Calciumchloride 40 µmol/ml TISSEEL contains Human Factor XIII co-purified with Human Fibrinogen in a range of 0.6 –5 IU/ml. 1, 2 or 5 ml deep-frozen component 1 (tissue protein solution with aprotinin) and 1, 2 or 5 ml deepfrozen component 2 (thrombin solution with calcium chloride). This gives a total volume of 2, 4 or 10 ml ready-to-use sealant solution when applied. **Indications:** Supportive treatment where standard surgical techniques appear insufficient: For improvement of hemostasis; As a tissue glue to improve wound healing or to support sutures in vascular surgery, in gastrointestinal anastomoses, in neurosurgery and in surgical interventions where contact with cerebrospinal fluid or dura mater may occur (e.g. in ENT, ophthalmic and spinal surgery); as a tissue adhesive, to promote the adhesion of the separated tissue (e.g. skin, tissue flaps, mesh). The efficacy in fully heparinised patients has been proven. **Contraindications:** Tisseel must not be applied intravascularly. Tisseel must not be applied in case of hypersensitivity to the active substances or to any of the excipients. For prescription, please refer to Full Product IFU. Prepared on Dec 2020

Baxter Healthcare Ltd.
Suite 2701-03, Oxford House, Taikoo Place, Quarry Bay, Hong Kong
T: (852) 2807 8500 F: (752) 2807 8596

HK-AS32-210004 October 2021

Baxter

Turn the blue light on to brighten up your GBM patient's day

OPTUNE
Elevate Expectations

TTFIELDS

At first GBM recurrence, keep Optune on to strive for a brighter future

For your newly diagnosed GBM patients, their new journey is safeguarded by a start with Optune

From the EF-14 study,*

5 Yrs Doubled 5-year survival rate[1]

13% with Optune plus TMZ vs. 5% with TMZ alone (p=0.004)[1]

HRQoL maintained over time with Optune[2]

Patients reflected that addition of Optune **did not affect HRQoL** except for more itchy skin[2]

From the EF-14 study,*

Improved overall survival beyond the first recurrence on Optune plus TMZ[3]

11.8 months with the continued use of Optune plus 2L systemic treatment vs. 9.2 months with 2L systemic treatment only (HR=0.70; 95%CI: 0.48-1.00; p=0.049)[3]

Low toxicity[3]

Toxicity profile was similar in patients treated with Optune + 2L chemotherapy after first recurrence compared with patients treated with Optune + TMZ as maintenance therapy[3]

Only 13% of Optune users reported a medical device site reaction, and none was severe[3]

*__Study design of the EF-14 study__[1,2]: In the multicenter, open-label, randomized, phase 3 EF-14 study, 695 patients with newly diagnosed GBM whose tumor had been resected or biopsied and had completed concomitant radiochemotherapy were randomized 2:1 to receive Optune plus TMZ or TMZ alone. The primary endpoint was PFS, and the secondary endpoint was OS. If tumor progression occurred, second-line therapy was offered per local practice. However, in the experimental group, Optune could be continued until second radiologic progression occurred or for a maximum of 24 months. A post hoc analysis was performed to evaluate the efficacy and safety of Optune when added to second-line treatment according to physician's best choice after first disease recurrence among the patients who were enrolled in the trial.

Abbreviations: 2L, second-line; GBM, glioblastoma multiforme; HRQoL, health-related quality of life; TMZ, temozolomide; TTFields, tumor-treating fields.

References: 1. Stupp R et al. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. *JAMA.* 2017;318(23):2306-2316. 2. Taphoorn MJB et al. Influence of treatment with tumor-treating fields on health-related quality of life of patients with newly diagnosed glioblastoma: a secondary analysis of a randomized-clinical trial. *JAMA Oncol*. 2018;4(4):495-504. 3. Kesari S et al. Tumor-treating fields plus chemotherapy versus chemotherapy alone for glioblastoma at first recurrence: a post hoc analysis of the EF-14 trial. *CNS Oncol.* 2017;6(3):185-193.

Indications for Use

Optune is intended as a treatment for adult patients (18 years of age or older) with histologically confirmed glioblastoma multiforme (GBM). **Newly diagnosed GBM** Optune (NovoTTF-200A) Treatment Kit is intended for the treatment of patients with newly diagnosed GBM, after surgery and radiotherapy with adjuvant Temozolomide, concomitant to maintenance Temozolomide. The treatment is intended for adult patients, 18 years of age or older, and should be started more than 4 weeks after surgery and radiation therapy with adjuvant Temozolomide. Treatment may be given together with maintenance Temozolomide (according to the prescribing information in the Temozolomide package insert) and after maintenance Temozolomide is stopped. **Recurrent GBM** Optune (NovoTTF-200A) Treatment Kit is intended for the treatment of patients with recurrent GBM who have progressed after surgery, radiotherapy and Temozolomide treatment for their primary disease. The treatment is intended for adult patients, 18 years of age or older, and should be started more than 4 weeks after the latest surgery, radiation therapy or chemotherapy. **Contraindications** *The directions below are written in the language directed to the patient.* Do not use Optune Treatment Kit if you are pregnant, think you might be pregnant, or are trying to get pregnant. If you are a woman who is able to get pregnant, you must use birth control when using the device. Optune Treatment Kit was not tested in pregnant women. Do not use Optune Treatment Kit if you have significant additional neurological disease (primary seizure disorder, dementia, progressive degenerative neurological disorder, meningitis or encephalitis, hydrocephalus associated with increased intracranial pressure). Do not use Optune Treatment Kit if you are known to be sensitive to conductive hydrogels like the gel used on electrocardiogram (ECG) stickers or transcutaneous electrical nerve stimulation (TENS) electrodes. In this case, skin contact with the gel used with Optune Treatment Kit may commonly cause increased redness and itching, and rarely may even lead to severe allergic reactions such as shock and respiratory failure. Do not use Optune if you have an active implanted medical device, a skull defect (such as, missing bone with no replacement) or bullet fragments. Examples of active electronic devices include deep brain stimulators, spinal cord stimulators, vagus nerve stimulators, pacemakers and defibrillators. Use of Optune together with implanted electronic devices has not been tested and may lead to malfunctioning of the implanted device. Use of Optune together with skull defects or bullet fragments has not been tested and may possibly lead to tissue damage or render Optune ineffective. Ref: Commercial Optune Physician Instructions For Use Version 1.1, Document number QSD-QR-711 EN(HK), Release date: Dec 2020.

Zai Lab is the authorized licensee of Novocure.

Patient images reflect the health status of the patient at the time each photo was taken.

zai Lab

Zai Lab (Hong Kong) Limited
Room 2301, 23/F, Island Place Tower, 510 King's Road, North Point, Hong Kong
Tel : +852 3844 8100 Fax : +852 3844 8188

HK-OPT-202105-01

PROGRAMME :
FREE PAPER SESSIONS
DAY 1

Free papers list

Sessions on 26 November 2021		
Free Paper I - Trauma Chairpersons: *Dr. K.Y. Pang & Dr. Christopher Poon*		
08:40 - 08:50	Does scheduled progress computed tomography of the brain alter management in patients with intracranial haemorrhage from traumatic brain injury?	*Ben Kin-long Luk*
08:50 - 09:00	The Role of Transamin in Treating Chronic Subdural Haematoma	*Cheuk-him Ho*
09:00 - 09:10	A Multicenter Study of Patients with Sports- and Recreational Cycling-Related Traumatic Brain Injury in Hong Kong	*Eric Y.H. Cheung*
09:10 - 09:20	Comparison of Quantitative Electroencephalography (qEEG) of patients of post-concussion syndrome (PCS) with healthy subjects: A preliminary study	*Ming-him Yuen*
09:20 - 09:30	Oxygen therapy for chronic subdural haematoma after burr-hole drainage? Faster pneumocephalus resorption with post-operative supplemental low-flow normobaric oxygen	*David Yuen-chung Chan*
09:30 - 09:40	Concomitant placement of intracranial pressure monitor during isolated acute subdural hematoma evacuation does not improve neurological outcomes	*Siang-liao Lee*
09:40 - 09:50	Traumatic Cerebrovascular Injury: A Retrospective Review in a Major Trauma Center in Hong Kong	*Wenzhe Ye*

PROGRAMME : FREE PAPER SESSIONS

DAY 1

Sessions on 26 November 2021		
Free Paper II - Vascular Chairpersons: *Dr. Y.T. Kan & Dr. C.P. Tsang*		
10:30 - 10:40	"Blood-Brain Matters" - A Study on the Clinical Impact of Anemia in Neurocritical Care of Ruptured Intracranial Aneurysms	*Carmen Yim*
10:40 - 10:50	Resource optimization to improve outcome in the timely treatment of large vessel stroke in Hong Kong	*Kai-yuen Pang*
10:50 - 11:00	Mechanical Thrombectomy in Octogenarians and Above with Large Vessel Occlusion - A Local Centre Experience	*Stephanie Yu*
11:00 - 11:10	Neurological Complications in Patients on Extracorporeal Membrane Oxygenation: Predictors, Outcomes, and Implications for Surgical Management	*Christopher Hiu-fung Sum*
11:10 - 11:20	Comparison of Transradial Versus Transfemoral Access for Interventional Neuro-endovascular Procedures: A Clinical and Technical Outcome Study	*Janet Hin-man Wong*
11:20 - 11:30	Inhibition of C-X-C Motif Chemokine Receptor 3 (CXCR3) improves the outcomes after intracerebral hemorrhage	*Anson Cho-kiu Ng*

Free Paper III - Spine Chairpersons: *Dr. Joseph Lam & Dr. Y.H. Tse*		
14:10 - 14:20	Is arthroplasty a better alternative to anterior spinal discectomy and fusion in patients suffered from cervical spinal degenerative disease?	*Ling-Kit Cheung*
14:20 - 14:30	Illustrative Case Series of the Degenerative Cervical Myelopathy: Dilemmas in Surgical Management	*Chang-keng Ma*
14:30 - 14:40	A case of bilateral cervical spondylolysis at the sixth cervical vertebra; review of literature and its surgical approach	*Bill Ka-biu Wong*
14:40 - 14:50	Tarlov Cyst - Image-guided Intervention	*Derek Wang-lin Ng*

PROGRAMME :
FREE PAPER SESSIONS
DAY 2

Free papers list

Sessions on 27 November 2021		
Free Paper IV (Video Session) Chairpersons: *Dr. Clarence Leung & Dr. T.C.Tan*		
10:20 - 10:40	ICG guided Extended Transsphenoidal Surgery for excision of recurrent craniopharyngioma	*Chat-fong Ng*
	Endoscopic Lumbar Interbody Fusion (EndoLIF) for "Failed Back Surgery" Syndrome	*David Yuen-chung Chan*
	Spinal arterio-venous malformation –intra-operative Indocyanine Green Angiography guidance excision	*Nok-lun Chan*
	Fukushima EC-IC Bypass in Treating Cavernous ICA Mycotic Aneurysm	*Marco Van-Boswell*

Free Paper V - Tumor & Others Chairpersons: *Dr. S.T. Chan & Dr. W.K. Wong*		
10:40 - 10:50	Glioblastoma Patient Survival Predictors Treated by the Hong Kong Hospital Authority: A Multicenter Retrospective 15-Year Review	*Sarah Sau-ning Lau*
10:50 - 11:00	Early outcome after transsphenoidal surgery for management of hormone secreting pituitary adenoma: a single centre experience in Hong Kong	*Jennie Shu-yan Yeung*
11:00 - 11:10	Effect of Orbitotomy on Surgical Freedom in Endoscopic Transorbital Approach (ETOA) to the skull base: An Anatomical Study	*Chat-fong Ng*
11:10 - 11:20	Timing of Stereotactic Radiosurgery after Resection of Brain Metastases - Does It Affect the Outcome?	*Wing-lok Cheung*
11:20 - 11:30	Sodium fluorescein guided surgery for high grade glioma - a 3-year review	*Kwan-chun Chan*
11:30 - 11:40	Outcome Analysis of Neuromodulative Surgery for Drug Refractory Epilepsy: A Review of 6-year Experience in Queen Elizabeth Hospital	*Wenzhe Ye*
11:40 - 11:50	Overview of the Etiologies & Outcomes of Traumatic Brain Injury in Different Pediatric Age Groups before and during the COVID-19 Pandemics	*Jian-feng Liu*
11:50 - 12:00	Open cranial vault remodeling vs Endoscopic suturectomy with post-operative helmet therapy for non-syndromic craniosynostosis	*Hung-yan Lau*

PROGRAMME :
FREE PAPER SESSIONS
DAY 2

Sessions on 27 November 2021		
Free Paper VI - Functional & Others Chairpersons: *Dr. K.H. Chan & Dr. Y.C. Po*		
13:40 - 13:50	Anterior nucleus of thalamus deep brain stimulation for refractory epilepsy: long term results of a prospective cohort study	*Eric Y.H. Cheung*
13:50 - 14:00	Application of Electromyogram for Deep Brain Stimulation under General Anaesthesia	*Laura Lok-wa Leung*
14:00 - 14:10	Does Repeat Resection for Recurrent Glioblastoma Improve Overall Survival? A Multi-Centre Review	*Tiffany H.P. Law*

Free Paper VII - Vascular Chairpersons: *Dr. K.M. Cheng & Dr. W.M. Lui*		
14:10 - 14:20	Use of PHIL and SQUID in embolization of cerebral arteriovenous malformation	*Eric Y.H. Cheung*
14:20 - 14:30	Ten Years of Experience in Intraoperative Angiogram for Intracranial Vascular Malformations	*Cheuk-him Ho*
14:30 - 14:40	Treatments in middle cerebral artery stenosis: a retrospective study	*Pak-to Yuen*
14:40 - 14:50	Mechanical Thrombectomy for In-Hospital Versus Community-Onset Ischemic Stroke: Comparison of Time Metrics, Technical and Clinical Outcomes	*Christopher Hiu-fung Sum*

PROGRAMME:
POSTER PRESENTATION
26 - 27 NOVEMBER 2021

Poster list

Ref. No.	Title	Author
P001	External ventricular drains in the treatment of subarachnoid haemorrhage with concurrent intraventricular haemorrhage	Adrian Sze-jin Yu
P002	Could unilateral Moyamoya vasculopathy be a response to repetitive head trauma? An Unusual Case of Subacute Subdural Hematoma with Chronic Middle Cerebral Artery Dissection, and Infarction in a Young Football Player	*Wui-chung Poon*
P003	Perceptions and Attitudes Toward Neurosurgery as a Career Choice Among Medical Students and Interns in Hong Kong	*Karin Kwun-yi Ho*
P004	Surviving Gliosarcoma: A Retrospective Single-Centre Review of Patient Survival	*Lucia Lam*
P005	Deep Brain Stimulation for Tourette syndrome: A Mini-case series	*William Xue*
P006	Lumbar Epidural Blood Patch: A safe treatment for intracranial hypotension	*Laura Lok-wa Leung*
P007	The Spatial and Temporal Dynamics of Microglia cells after Focal Cerebral Ischemia	Cyrus Wing-chung Cheng
P008	Role of vitamin D deficiency in intracerebral haemorrhage in mice model	*Tsz-lung Lam*
P009	Clinical Outcome and Utility of Brain Biopsy in Patients with Suspected CNS Lymphoma	*Cheuk-him Ho*
P010	Emergency Versus Elective Brain Tumor Excisions: A 3-Year Propensity Score Matched Outcome Analysis	*Christopher Hiu-fung Sum*
P011	Early Experience of SEEG in Non-lesional Refractory Epilepsy: a Case Illustration	*Shek-ching Lam*
P012	Less invasive approach for total resection of paraspinous dumbbell shaped neuogenic neoplasm of the spine	*Ka-kin Chan*
P013	MRI in Patients with High Grade Glioma - Pseudoprogression and Recurrence	*Natalie Iris Tze-ying Ho*
P014	Is the scientific basis of wakefulness sufficient to guide Neurosurgical management in the care of patients in a persistent vegetative state in Hong Kong? A medico-legal analysis	*Karen Ka-wai Lam*
P015	Diastematomyelia: Case Report of a Rare Disease and Its Operative Repair	*Le Lyu*
P016	Newborn with Large Open Myelomeningocele Associated with Kyphoscoliosis: A Case Report	*Ray Yip-mang O*
P017	Malignant melanoma presenting with brain metastases: three case reports in an Asian population	*Robin Wong*
P018	Non-traumatic paediatric intracranial haemorrhage in children - case series in Hong Kong	*Jacqueline Chak-lam Fung*
P019	Complications of Post-craniectomy Cranioplasty: a Retrospective Study and Risk Factor Analysis	*Mei-ting Wong*

PROGRAMME:
POSTER PRESENTATION
26 - 27 NOVEMBER 2021

Ref. No.	Title	Author
P020	Use of Split Spinous Process Sublaminar Decompression Technique for resecting Intradural Spinal Lesion	*Hing-chi Wong*
P021	Infant with cutis aplasia congenita, encephalocele, and syntelencephaly: a case report	*Hung-yan Lau*
P022	A single-center, retrospective study of Intraventricular thrombolysis outcome on intraventricular haemorrhage	*Jing-woei Li*
P023	Novel Surgical Technique for Parapharyngeal Liposarcoma: Case Report of a Rare Disease and Literature Review	*Wang-lin Ng*
P024	A Retrospective Multicenter Study Identifying Predictive Factors for Glioblastoma Gross Total Resection	*Saori Takemura*
P025	Fluorescein-guided neurosurgery, clinical use and experience share	*Hing-fai Cheng*
P026	Role of Wada test and neuropsychological assessment in the management of patients with medically intractable epilepsy	*Yu-him Lau*
P027	A high fidelity and modality simulation in delivering knowledge and hands-on skills to manage tracheostomy emergencies	*Chin-man Tsang*
P028	A Clinical Investigation Evaluating the Efficacy of Olfactory Training by Two Olfactory Tests in Healthy Subjects	*Queenie Hoi-wing Wong*

CardinalHealth
Essential to care®

Kendall SCD™ 700 Sequential Compression System

CUSTOMISED THERAPY. CLINICALLY PROVEN SOLUTION.

Help reduce venous thromboembolism (VTE) with the Kendall SCD™ 700 Sequential Compression System

Vascular Refill Detection (VRD) function available

VRD is unique to the Kendall SCD™ 700 Sequential Compression System. It has been clinically proven to move up to 76% more blood over time when compared with IPC devices without VRD.*

Animated alerts

Animated icons show the cause of an error and how it can be resolved.*

Durable

Limited liquid ingress (rating of IPX3), robust Xylex material, and fully protected battery.*

Reduced noise

Soft overmolding with vibration dampeners make the controller quiet.*

Easy-to-clean

Smooth, grooveless surfaces and slim profile; compatible with most hospital-grade cleaning agents.*

* Internal data Available Upon Request

ZP THERAPEUTICS
making healthcare more accessible

ZP Therapeutics, a division of Zuellig Pharma Limited, a company incorporate in Hong Kong with its registered address at Suite 608, 6/F, Devon House, Taikoo Place, Quarry Bay, Hong Kong. Tel: 852 2856 3632 Website: www.zuelligpharma.com

Explore the Clinical Evidence Resource of VTE Prevention

SCD 700 Smart Compression System Overview in YouTube

HK-ZPT-CAHSCD001-001

OPTIMUS NEURO

The universal and reliable plates and screw solution

AAG002/OptiNeu/21/NOV

Aesculap Endoscopic Technology
Aesculap – a B. Braun company

B. Braun Medical (H.K.) Ltd.
Tel: +852 2277 6100 Fax: +852 2865 6095
www.bbraun.com.hk

B|BRAUN
SHARING EXPERTISE

PROGRAMME : NURSING SESSION

Nursing Session list

27 November 2021		
Excellence in Neurocritical Patient Care Journey Chairpersons: *Mr Ming-kei Chu & Ms Ming-yui Lok*		
10:40 - 10:50	To promote the implementation of National Institutes of Health Stroke Scale (NIHSS) in Department of Neurosurgery	*Sui-fung Fung*
10:50 - 11:00	Launching a "Nursing Management for Patients with Ventriculoperitoneal (VP) Shunts" Education Workshop for the Nursing Staff in Prince of Wales Hospital, and Tuen Mun Hospital under Hospital Authority	*Hung-wah Yeung*
11:00 - 11:10	Enhanced Infection Control Measures in Department of Neurosurgery	*Ming-wai Lam*
11:10 - 11:20	Mechanical Prophylaxis of Deep Vein Thrombosis (DVT) in Neurosurgery: Introduction of an Evidenced-Based Guideline	*Wai-kit Li*
11:20 - 11:30	Happy discharge, safe at home: The Neurosurgery Extended Care Program (Trial)	*Kin-man Kwok*
11:30 - 11:40	Q&A & Discussion	

Next-Generation Innovation From the Global Leader in Neurosurgery

The Codman® Electrosurgical Generator System

Engineered for controlled energy delivery to reduce sticking and charring.*

*When used with Codman forceps.

Codman
SPECIALTY SURGICAL

Codman® Electrosurgical Generator System

A DIVISION OF INTEGRA LIFESCIENCES

integralife.com

NewTech
International Trading Limited
Newtech International Trading Limited

RICHARD WOLF
spirit of excellence

Takes the pressure

Today, the instrument sets available permit a full-endoscopic approach under visualization, depending on the indication criteria, which is equivalent to conventional operations. While lateral, stenosis with symptoms on one side can be frequently operated using the basic instrument set, the larger Stenosis System can be used to operate on advanced cases or central stenosis. It is always important to consider whether a stabilizing measure is necessary in addition to decompression.

Center for Spine Surgery and Pain Therapy
Head: Priv.-Doz. Dr. med. habil. Sebastian Ruetten

ST. ELISABETH GRUPPE
KATHOLISCHE KLINIKEN RHEIN-RUHR

Center for Orthopedics and Traumatology
of the St. Elisabeth Group – Catholic Hospitals Rhein-Ruhr
St. Anna Hospital Herne/Marienhospital Herne University Hospital/Marien Hospital Witten
Director: Prof. Dr. med. Georgios Godolias

VERTEBRIS stenosis

Full-endoscopic, interlaminar decompression in case of lumbar spinal canal stenosis

ACKNOWLEDGEMENTS

The Organising Committee would like to extend their heartfelt thanks to

Platinum Sponsor

UPH Limited

Karl Storz Endoscopy China Limited

Gold Sponsor

Baxter Healthcare Limited

Medtronic Hong Kong Medical Limited

Mizuho Medical / Innoflx Limited

Stryker China Limited

Zai Lab (Hong Kong) Limited

Zuellig Pharma Limited

Allergan Hong Kong Limited

B. Braun Medical (HK) Limited

MontsMed Company Limited

NewTech International Trading Limited

Prism Technologies Limited

Johnson & Johnson (HK) Limited

Getinge Group Hong Kong Limited

Synapse Therapeutics Limited

for the generous support and contribution to

28th Annual Scientific Meeting
The Hong Kong Neurosurgical Society Limited

NEVER SETTLE. DEBULK THE BEAST!

Remove fibrous tissue swiftly and safely

CUSA® Clarity Ultrasonic Tissue Ablation System with Tough Tissue Technology enables you to debulk the toughest tissue.

INTEGRA®
LIMIT UNCERTAINTY

稜科有限公司
PRISMTECH
Authorized Distributor in Hong Kong & Macau

CUSA® Clarity

Debulking, Optimized.

TRUST BOTOX®

For upper limb spasticity associated with stroke in adults[1]

Help reduce the pain associated with Post-Stroke Spasticity [2]

Up to one-third of post-stroke spasticity patients treated with BOTOX® experienced pain reduction (n=111) [2]



The reduction in mean pain response was **sustained across 4 treatment cycles** with BOTOX® (n=110, 94, 77, 25) [2]

Help patients achieve their functional goals [3]



...of wrist and finger spasticity patients reported improvements toward their functional goals at Week 6 (n=62, p<0.001 versus placebo)[3]

Reference:
1. BOTOX Prescribing Information May 2013. 2. Gordon MF, et al. Neurology. 2004;63(10):1971-1973 3. Brashear A, et al. N Engl J Med. 2002;347(6):395-400.

BOTOX® Abbreviated Product Information

Active Ingredient & Strength: Each vial of BOTOX® contains 100 Units (U) of Botulinum Toxin Type A, as a haemagglutinin complex, 0.5 milligrams of human albumin and 0.9 milligrams of sodium chloride in a sterile, vacuum-dried preparation without a preservative. **Indication:** Strabismus and blepharospasm associated with dystonia, including benign essential blepharospasm or VII nerve disorders in patients ≥12 years old. Spasmodic torticollis (cervical dystonia) in adults. Dynamic equinus foot deformity due to spasticity in juvenile cerebral palsy patients ≥ 2 years old. Severe primary hyperhidrosis of the axilla. Wrist and hand disability due to upper limb spasticity associated with stroke in adults. Prophylaxis of headaches in adults with chronic migraine. Bladder dysfunction in adults, including urinary incontinence due to detrusor overactivity associated with a neurologic condition and overactive bladder. **Dosage and Method of Use:** Strabismus Initial doses in Units. A. For vertical muscles and for horizontal Strabismus of less than 20 prism diopters (PD): 1.25 to 2.5 U in any one muscle. B. For horizontal strabismus of 20 to 50 PD: 2.5 to 5.0 U in any one muscle. C. For persistent VII nerve palsy of one month or longer duration: 1.25 to 2.5 U in medial rectus muscle. Blepharospasm 1.25 to 2.5 U (0.05 to 0.1 mL volume at each site) injected into medial and lateral pre-tarsal orbicularis oculi of upper lid and into lateral pre-tarsal orbicularis oculi of lower lid. VII Nerve Disorders (Hemifacial Spasm) should be treated as for unilateral blepharospasm. Cervical Dystonia (Spasmodic Torticollis) Dosing must be tailored to the individual based on the patient's head and neck position, localisation of pain, muscle hypertrophy, patient's bodyweight, and patient response. Type I (Head rotated toward side of shoulder elevation), injection to Sternocleidomastoid (50-100 U; at least 2 sites), Levator scapulae (50 U; 1-2 sites), Scalene (25-50 U; 1-2 sites), Splenius capitis (25-75 U; 1-3 sites), Trapezius (25-100 U; 1-8 sites). Type II (Head rotation only), injection to Sternocleidomastoid (25-100 U; at least 2 sites if >25 U given). Type III (Head tilted toward side of shoulder elevation), Sternocleidomastoid (25-100 U; at posterior border; at least 2 sites if >25 U given), Levator scapulae (25-100 U; at least 2 sites), Scalene (25-75 U; at least 2 sites), Trapezius (25-100 U; 1-8 sites). Type IV (Bilateral posterior cervical muscle spasm with elevation of the face), injection to Splenius capitis and cervicis (50-200 U; 2-8 sites, treat bilaterally) Spasticity in Juvenile Cerebral Palsy Patients (≥2 years old) 4 U/kg administered by injecting 2 cc of reconstituted BOTOX® into each of two sites in medial and lateral heads of gastrocnemius muscle of the affected lower limb(s). Primary Hyperhidrosis of the Axillae 50 U of BOTOX® (2.0 mL) is injected intradermally to each axilla in multiple sites. Focal Spasticity associated with Stroke in Adults The exact dosage and number of injection sites should be tailored to the individual. In controlled Phase 3 clinical trial, following doses were used: flexor digitorum profundus(50 U), flexor digitorum sublimis(50 U), flexor carpi radialis(50 U), flexor carpi ulnaris (50 U), adductor pollicis(20 U), flexor pollicis longus(20 U). In all clinical trials, the doses did not exceed 360 U divided among selected muscles at any treatment session. Chronic migraine Intramuscularly (IM) injections of 0.1mL (5 U) to 31 up to 39 sites, across 7 areas: frontalis(20 U), corrugator(10 U), procerus (5 U), occipitalis (30 to 40 U), temporalis(40 to 50 U), trapezius(30 to 50 U), cervical paraspinal Muscle Group (20 U). Bladder Dysfunction Detrusor Overactivity associated with a Neurologic condition: 30 injections of 1mL (=6.7 U) each, with total 200 U/30mL into detrusor muscle. Overactive Bladder: 20 injections of 0.5mL (5 U) each, with total 100 U/10mL into detrusor muscle. **Contraindications:** Individuals with known hypersensitivity to any ingredient in the formulation. Patients with myasthenia gravis or Eaton Lambert Syndrome. BOTOX® is contraindicated in the presence of infection at the proposed injection site(s). Intradetrusor injection is contraindicated in patients with urinary retention and in patients with post-void residual urine volume >200 mL, who are not routinely performing clean intermittent self-catheterization (CIC) **Warnings and Precautions:** The safe and effective use of Botox® depends upon proper storage of product, selection of the correct dose, and proper reconstitution and administration techniques. The potency Units of Botox® are not interchangeable with other preparations of botulinum toxin products. Post-marketing safety data from BOTOX® and other approved botulinum toxins suggest that botulinum toxin effects may, in some cases, be observed beyond the site of local injection. Precautions may be needed in, but not limited to, pregnancy, nursing mothers, carcinogenesis, mutagenesis, impairment of fertility, pediatric/geriatric use. **Adverse Events:** Localized pain, tenderness and/or bruising; local muscle weakness; fever and flu syndrome; skin rash, pruritus, allergic reaction; eyelid ptosis, vertical deviation; irritation/tearing/keratitis of eye, ectropion/entropion, ecchymosis of eyelid, diplopia; blurring of vision, facial droop, dizziness, and tiredness; neck pain, asthenia, headache, injection site pain, dysphagia; falling, leg pain, leg weakness, or general weakness; perceived increase in non-axillary sweating, vasodilation(hot flushes); migraine, musculoskeletal stiffness/pain, myalgia, facial paresis, muscle spasms/tightness, pain in jaw, pain of skin; urinary tract infection, dysuria, urinary retention, bacteriuria, hematuria, residual urine volume, fatigue, insomnia. There are rare reports of death, sometimes associated with dysphagia, pneumonia, and/or other significant debility; rare reports involving cardiovascular system, including arrhythmia and myocardial infarction. **Please read the full prescribing information before prescribing. Full prescribing information is available upon request. HK_API Botox PI May 2013**

For healthcare professionals only. All adverse event should be reported to drugsafety.pv@abbvie.com

Allergan an AbbVie company

Allergan Hong Kong Limited
Suite 2404, 24/F, AIA Tower, 183 Electric Road, North Point, Hong Kong.
Tel: +852 3467 8888 Fax: +852 2219 7397

BOTOX® Botulinum Toxin Type A

HK-BTX-2050017 NOV2021

DePuy Synthes
THE ORTHOPAEDICS COMPANY OF Johnson & Johnson

CRANIAL CLOSURE

A comprehensive range of solutions for every type of cranial closure procedure

- MatrixNEURO™ Fixation System
- RAPIDSORB® Resorable Fixation System
- PEEK Milled Implants (PEEK PSI)



LivaNova

Epilepsy

LivaNova VNS Therapy™ is proven to protect against focal and generalized seizures[1]

LivaNova VNS Therapy™ is:

1. An adjunctive therapy for **focal** and **generalized seizures**[1]
2. Suitable for **adults** and **children**[1]
3. Implanted in a simple, **short day case procedure**[2]
4. Proven **efficacy** and **safety profile**[3,4]

LivaNova's VNS Therapy™ recommended in guidelines[5,6]

VNS Therapy™ is recommended by guidelines as an add-on therapy for reducing seizure frequency in children and adults who have failed to improve with two or more drugs (alone or in combination) and are not suitable for resective surgery.[5,6]

1. VNS Therapy System Physician's Manual (May 2019). **2.** Patient's Manual for Epilepsy (October 2017). **3.** The Vagus Nerve Stimulation Study Group. (1995) A randomized controlled trial of chronic vagus nerve stimulation for treatment of medically intractable seizures. The Vagus Nerve Stimulation Study Group. *Neurology*. 45(2):224-230. **4.** Handforth, A., *et al*, (1998) Vagus nerve stimulation therapy for partial-onset seizures: a randomized active-control trial. *Neurology*. 51:48-55. **5.** Morris, GL., *et al*, (2013) Evidence-based guideline update: vagus nerve stimulation for the treatment of epilepsy: report of the Guideline Development Subcommittee of the American Academy of Neurology. *Neurology*. 81:1453-9. **6.** National Institute for Health and Care Excellence (2012) Epilepsies: diagnosis and management. NICE guideline (CG137).

One Room, Multiple Uses

- the possibilities are endless

Getinge solutions for Hybrid ORs

From MR-compatible ventilators to tables and everything in between, Getinge has created a product offering for Hybrid suites that is second to none. The elements complement each other for seamless interaction and an ergonomic user experience. We go beyond individual products and deliver complete multidisciplinary solutions that suit all professional disciplines within the Hybrid OR environment.

Tel.: (852) 2207 6111 Email: sales.hk@getinge.com
www.getinge.com

GETINGE

Boston Scientific
Advancing science for life™

VERCISE™
DIRECTIONAL
Deep Brain Stimulation Systems

VERCISE GENUS™ DEEP BRAIN STIMULATION SYSTEM*

CONTROL MADE CLEAR

Combining Multiple Independent Current Control (MICC), novel directional capabilities, and integrated visualization of patient anatomy, the Vercise Genus DBS System offers unprecedented control for improved patient outcomes.

PRECISION MADE PERSONAL

Every brain is unique. So we created a DBS system that's uniquely customizable for every patient.

- Comprehensive MRI conditional** DBS portfolio
- Personalize therapy stimulation with Cartesia™ 3D

SIMPLY INTUITIVE

Vercise Genus features an intelligent interface to help simplify programming using Neural Navigator 4 software.

- Integrated visualization of patient-specific anatomy with STIMVIEW™ XT
- Optimize controls for simplified programming

CONVENIENCE MEETS COMFORT

The Vercise Genus DBS system's small, thin IPGs are equipped with Bluetooth connectivity to provide enhanced communication and ease of use.

- 11 mm thin, Genus IPGs are designed with patient comfort in mind

*A System that includes the Vercise Genus IPG and Vercise Cartesia™ Directional Lead(s) forms the Vercise Directional System

Not available in all markets. Vault-free based on typical system use and patient volume.

FIRST-IN-KIND. VAULT-FREE. COBALT-FREE.

World-class radiosurgery to treat more patients in more places.

Take an interactive tour of ZAP-X®:
zapsurgical.com/vr-tour

UPH Limited
E: tcy@up-healthcare.com | **P:** +852-92832429

ZAP®

THAT WAS THEN. **THIS IS NEXT.**